Open-label dose confirmation and dosimetry study of interstitial 131I-chTNT-1/B mAb (Cotara) for the treatment of recurrent glioblastoma multiforme.
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Iodine I 131 derlotuximab biotin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Peregrine Pharmaceuticals
- 14 Mar 2011 Results will be presented by mid-2011.
- 31 Dec 2010 Status changed from active, no longer recruiting to completed.
- 13 Apr 2010 Results will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.